Associations between neurofilament light and imaging biomarkers of Alzheimer’s disease

Takeaway

  • Plasma neurofilament light (NfL), a marker of neuroaxonal injury, increases in response to amyloid-related neuronal injury in the preclinical stages of Alzheimer’s disease (AD) and tau-mediated neurodegeneration in the symptomatic course of the disease.

Why this matters

    Plasma NfL may be a beneficial biomarker of detecting early neuronal damage in neurodegenerative diseases, such as AD and monitoring treatment effects in drug trials.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.